Bayer Launches Phase IIa Trial of BAY 3401016 for Alport Syndrome
I'm PortAI, I can summarize articles.
Bayer AG has initiated a Phase IIa clinical trial for BAY 3401016, targeting Semaphorin 3A in Alport Syndrome. The ASSESS trial is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of BAY 3401016 in adult patients. The drug has received Fast Track and Orphan Drug Designation from the U.S. FDA. The study has just commenced, and results are not yet available.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments